Presentation is loading. Please wait.

Presentation is loading. Please wait.

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer 

Published byΝύξ Βυζάντιος Modified over 5 years ago

Similar presentations

Presentation on theme: "Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer "— Presentation transcript:

1 Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer  Andrew J. Weickhardt, MBBS, DmedSc, Benjamin Scheier, MD, Joseph Malachy Burke, MD, Gregory Gan, MD, Xian Lu, MSc, Paul A. Bunn, MD, Dara L. Aisner, MD, PhD, Laurie E. Gaspar, MD, MBA, Brian D. Kavanagh, MD, MPH, Robert C. Doebele, MD, PhD, D. Ross Camidge, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 12, Pages (December 2012) DOI: /JTO.0b013e Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, PFS1 and PFS1+PFS2 survival curves of all 25 patients treated with LAT. B, Ten patients treated with LAT who first progressed only in the CNS. C, Fifteen patients treated with LAT who first progressed in extra-CNS locations, including three patients with simultaneous CNS and eCNS progression. PFS1, median progression-free survival; PFS2, progression-free survival from the time of first progression; LAT, local ablative therapy; CNS, central nervous system; eCNS, extra-CNS. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Proposed schema for incorporating local ablative therapy into therapy at time of first progression with ALK+ or EGFR-MT NSCLC patients treated with TKI therapy. ALK+, anaplastic lymphoma kinase gene rearrangement; EGFR-MT NSCLC, epidermal growth factor receptor-mutant non–small-cell lung cancer; TKI, tyrosine kinase inhibitors. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer "

Similar presentations

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Similar presentations

Ads by Google